We previously reported an effect of MerTK inhibition on PD-L1 and PD-L2 expression in acute lymphoblastic leukemia (ALL) (21), however, given the vast differences between these diseases and the microenvironments they create within the spleen and BM, we evaluated LAM PD-L1 and PD-L2 expression in mice inoculated with MLL-ENL AML treated with MRX2843 (or vehicle), and non-leukemic mice (control). The gene discussed is KMT2A; the disease is acute myeloid leukemia.